Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$35.08M, compared with -$37.57M a year earlier. Trailing-twelve-month EBITDA was -$130.98M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$130.71M (+9.4%) for the fiscal year ending Dec 2026, a slowdown from the +22.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$35.08M-1.3% QoQ
- Last fiscal yearDec 2025
- -$144.27M+22.5% YoY
- LTMMar 2026
- -$130.98M+37.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.6% | — | — |
| 1 year | +22.5% | +9.4% | -13.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (144.27M) USD
- Year-over-year change
- +22.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (144.27M) | +22.5% |
| FY2024 | 2024-12-31 | (186.17M) | +24.8% |
| FY2023 | 2023-12-31 | (247.6M) | -6.0% |
| FY2022 | 2022-12-31 | (233.58M) | -12.7% |
| FY2021 | 2021-12-31 | (207.2M) | — |
EBITDA vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 EBITDA of -$130.98M is the lowest of the 11 companies compared; the peer median is -$67.54M.
- Its year-over-year change of +37.9% is the 4th highest of 11, against a peer median of +11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$34.56M | -66.8% | — | — | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$41.59M | +38.3% | — | — | |
| LTM Mar 2026 | -$46.23M | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M | -35.4% | — | — |
| LTM Mar 2026 | -$86.7M | +32.0% | — | — | |
| LTM Mar 2026 | -$106.12M | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$107.98M | +49.6% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M | +37.9% | — | — | |
| Peer median (excluding ZNTL) | -$67.54M | +11.9% | — | 98.1% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 67.43M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 67.43M | 0 |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M |
| Selling, General & Admin | 40.94M | 54.55M | 59.4M | 87.12M | 37.72M |
| Operating Expenses | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| EBITDA | (207.2M) | (233.58M) | (247.6M) | (186.17M) | (144.27M) |
| EBITDA Margin | — | — | — | -276.1% | — |
| Operating Income | (216.54M) | (227.29M) | (299.51M) | (191.19M) | (152.81M) |
| Operating Margin | — | — | — | -283.6% | — |
| Interest Income | 0 | 2.26K | 0 | 0 | 0 |
| Interest Expense | 0 | 2.58M | 0 | 0 | 0 |
| Other Income / Expenses | 50.15M | (10.3M) | 6.6M | 25.5M | 16.19M |
| Income Before Tax | (166.39M) | (237.58M) | (292.91M) | (165.69M) | (136.62M) |
| Pre-Tax Margin | — | — | — | -245.7% | — |
| Income Tax Expense | (297K) | (469K) | (601K) | 177K | 442K |
| Net Income | (158.73M) | (236.81M) | (292.19M) | (165.84M) | (137.06M) |
| Net Margin | — | — | — | -246.0% | — |
| EPS (Basic) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| EPS (Diluted) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| Weighted Avg Shares | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
| Weighted Avg Shares (Diluted) | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.